Item Type | Name |
Concept
|
Acquired Immunodeficiency Syndrome
|
Concept
|
Alleles
|
Concept
|
Antigens, Surface
|
Concept
|
Carcinoma, Squamous Cell
|
Concept
|
Computer Simulation
|
Concept
|
Base Sequence
|
Concept
|
Digestive System
|
Concept
|
Carcinoma, Non-Small-Cell Lung
|
Concept
|
Evaluation Studies as Topic
|
Concept
|
Complement System Proteins
|
Concept
|
Uterine Cervical Neoplasms
|
Concept
|
Crigler-Najjar Syndrome
|
Concept
|
Drug Synergism
|
Concept
|
Cytochrome P-450 Enzyme System
|
Concept
|
Decision Support Techniques
|
Concept
|
Educational Status
|
Concept
|
Gas Chromatography-Mass Spectrometry
|
Concept
|
Digestive System Diseases
|
Concept
|
Drug Stability
|
Concept
|
Drug Utilization
|
Concept
|
Feasibility Studies
|
Concept
|
Hypnotics and Sedatives
|
Concept
|
Health Services Accessibility
|
Concept
|
Product Surveillance, Postmarketing
|
Concept
|
Molecular Sequence Data
|
Concept
|
Myelodysplastic Syndromes
|
Concept
|
Nervous System Diseases
|
Concept
|
Neoplasm Staging
|
Concept
|
Safety
|
Concept
|
Peripheral Nervous System Diseases
|
Concept
|
Sex Characteristics
|
Concept
|
Frozen Sections
|
Concept
|
Reference Standards
|
Concept
|
Research Support as Topic
|
Concept
|
Soft Tissue Neoplasms
|
Concept
|
Species Specificity
|
Concept
|
Cohort Studies
|
Concept
|
Genes, ras
|
Concept
|
Sensory Receptor Cells
|
Concept
|
Shivering
|
Concept
|
Smoking
|
Concept
|
Specialization
|
Concept
|
Stomatitis
|
Concept
|
Sensitivity and Specificity
|
Concept
|
Singapore
|
Concept
|
Mass Spectrometry
|
Concept
|
Splenectomy
|
Concept
|
Societies, Medical
|
Concept
|
Sulfonic Acids
|
Concept
|
Software
|
Concept
|
Statistics as Topic
|
Concept
|
United States
|
Concept
|
United States Food and Drug Administration
|
Concept
|
Students
|
Concept
|
Succinylcholine
|
Concept
|
Syndrome
|
Concept
|
Uridine Diphosphate
|
Concept
|
Universities
|
Concept
|
Multicenter Studies as Topic
|
Concept
|
Sulfotransferases
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
Concept
|
Substance-Related Disorders
|
Concept
|
Werner Syndrome
|
Concept
|
Up-Regulation
|
Concept
|
Neoplasms, Second Primary
|
Concept
|
Salvage Therapy
|
Concept
|
Chi-Square Distribution
|
Concept
|
Least-Squares Analysis
|
Concept
|
Cost Savings
|
Concept
|
Private Sector
|
Concept
|
Rats, Sprague-Dawley
|
Concept
|
Drug Delivery Systems
|
Concept
|
Case-Control Studies
|
Concept
|
Alternative Splicing
|
Concept
|
Sequence Analysis, DNA
|
Concept
|
Prostate-Specific Antigen
|
Concept
|
Protein Structure, Tertiary
|
Concept
|
Genes, Reporter
|
Concept
|
National Institutes of Health (U.S.)
|
Concept
|
Consensus Sequence
|
Concept
|
Sequence Deletion
|
Concept
|
Neoplasms, Squamous Cell
|
Concept
|
Sample Size
|
Concept
|
Decision Support Systems, Clinical
|
Concept
|
Sepsis
|
Concept
|
Cross-Over Studies
|
Concept
|
Public Sector
|
Concept
|
In Situ Hybridization, Fluorescence
|
Concept
|
Carcinoma, Small Cell
|
Concept
|
Amino Acid Substitution
|
Concept
|
Oligonucleotide Array Sequence Analysis
|
Concept
|
3' Untranslated Regions
|
Concept
|
Health Care Sector
|
Concept
|
Sirolimus
|
Concept
|
Organic Anion Transporters, Sodium-Independent
|
Concept
|
Surveys and Questionnaires
|
Concept
|
National Cancer Institute (U.S.)
|
Concept
|
Sarcoma
|
Concept
|
Serum Albumin
|
Concept
|
Severity of Illness Index
|
Concept
|
Tandem Mass Spectrometry
|
Concept
|
DNA Breaks, Double-Stranded
|
Concept
|
Schools, Medical
|
Concept
|
Snake Venoms
|
Concept
|
Stomach Neoplasms
|
Concept
|
Structure-Activity Relationship
|
Concept
|
Sulfonamides
|
Concept
|
TOR Serine-Threonine Kinases
|
Concept
|
High-Throughput Nucleotide Sequencing
|
Concept
|
Human Umbilical Vein Endothelial Cells
|
Concept
|
Uracil
|
Concept
|
Sex Factors
|
Concept
|
Skin Neoplasms
|
Concept
|
Spectrophotometry, Ultraviolet
|
Concept
|
Stereoisomerism
|
Concept
|
Substrate Specificity
|
Concept
|
Adaptor Proteins, Signal Transducing
|
Concept
|
Suramin
|
Concept
|
Models, Statistical
|
Concept
|
Selection Bias
|
Concept
|
Survival Analysis
|
Concept
|
Thymidylate Synthase
|
Concept
|
Patient Satisfaction
|
Concept
|
Molecular Structure
|
Concept
|
Survivors
|
Concept
|
Genome, Human
|
Concept
|
Survival Rate
|
Concept
|
Lymphocyte Subsets
|
Concept
|
Granulocyte Colony-Stimulating Factor
|
Concept
|
Patient Selection
|
Concept
|
Cost Sharing
|
Concept
|
Karnofsky Performance Status
|
Concept
|
Dietary Supplements
|
Concept
|
Statistics, Nonparametric
|
Concept
|
HSP90 Heat-Shock Proteins
|
Concept
|
MAP Kinase Signaling System
|
Concept
|
Medical Order Entry Systems
|
Concept
|
Genome-Wide Association Study
|
Concept
|
Ribosomal Protein S6 Kinases, 70-kDa
|
Concept
|
Intracellular Signaling Peptides and Proteins
|
Concept
|
Genes, Neoplasm
|
Concept
|
Anemia, Sickle Cell
|
Concept
|
Body Surface Area
|
Concept
|
Cell Survival
|
Concept
|
Data Interpretation, Statistical
|
Concept
|
Drug Administration Schedule
|
Concept
|
Drug Screening Assays, Antitumor
|
Concept
|
Follow-Up Studies
|
Concept
|
Injections, Subcutaneous
|
Concept
|
Longitudinal Studies
|
Concept
|
Professional Staff Committees
|
Concept
|
Prospective Studies
|
Concept
|
Retrospective Studies
|
Concept
|
Serine Endopeptidases
|
Concept
|
Social Perception
|
Concept
|
User-Computer Interface
|
Concept
|
Signal Transduction
|
Concept
|
Granulocyte-Macrophage Colony-Stimulating Factor
|
Concept
|
Conserved Sequence
|
Concept
|
Disease-Free Survival
|
Concept
|
Point-of-Care Systems
|
Concept
|
Polymorphism, Single Nucleotide
|
Concept
|
Research Subjects
|
Concept
|
Quantitative Trait Loci
|
Concept
|
Genetic Loci
|
Concept
|
Patient Safety
|
Academic Article
|
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
|
Academic Article
|
Phase I study of amonafide dosing based on acetylator phenotype.
|
Academic Article
|
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a.
|
Academic Article
|
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
|
Academic Article
|
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
|
Academic Article
|
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support.
|
Academic Article
|
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
|
Academic Article
|
Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision.
|
Academic Article
|
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
|
Academic Article
|
Individualizing dosing of cancer chemotherapy.
|
Academic Article
|
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
|
Academic Article
|
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
|
Academic Article
|
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
|
Academic Article
|
Keratoacanthomas and skin neoplasms associated with suramin therapy.
|
Academic Article
|
Mineralocorticoid insufficiency due to suramin therapy.
|
Academic Article
|
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
|
Academic Article
|
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
|
Academic Article
|
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
|
Academic Article
|
Therapeutic relevance of pharmacokinetics and pharmacodynamics.
|
Academic Article
|
Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.
|
Academic Article
|
Data modifications to phase I study of suramin.
|
Academic Article
|
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
|
Academic Article
|
New phase I trial methodology.
|
Academic Article
|
Suramin: is adaptive control necessary?
|
Academic Article
|
Learning from our patients: one participant's impact on clinical trial research and informed consent.
|
Academic Article
|
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
|
Academic Article
|
Study of cohort-specific consent and patient control in phase I cancer trials.
|
Academic Article
|
Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry.
|
Academic Article
|
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
|
Academic Article
|
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule.
|
Academic Article
|
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
|
Academic Article
|
Evaluation of neuropathy in patients on suramin treatment.
|
Academic Article
|
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
|
Academic Article
|
Promising new agents in oncologic treatment.
|
Academic Article
|
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.
|
Academic Article
|
Oral chemotherapy: rationale and future directions.
|
Academic Article
|
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
|
Academic Article
|
New perspectives on the toxicity of etoposide.
|
Academic Article
|
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
|
Academic Article
|
Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia.
|
Academic Article
|
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
|
Academic Article
|
Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.
|
Academic Article
|
Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
|
Academic Article
|
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
|
Academic Article
|
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
|
Academic Article
|
Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.
|
Academic Article
|
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
|
Academic Article
|
Clinical pharmacology of camptothecins.
|
Academic Article
|
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
|
Academic Article
|
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
|
Academic Article
|
Insights into the pharmacokinetics and pharmacodynamics of irinotecan.
|
Academic Article
|
Rationale for phase I study of UFT plus leucovorin and oral JM-216.
|
Academic Article
|
Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?
|
Academic Article
|
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
|
Academic Article
|
Limited sampling model for area under the concentration time curve of total topotecan.
|
Academic Article
|
Pharmacogenetics and cancer chemotherapy.
|
Academic Article
|
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients.
|
Academic Article
|
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
|
Academic Article
|
Pharmacogenetics in cancer etiology and chemotherapy.
|
Academic Article
|
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
|
Academic Article
|
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
|
Academic Article
|
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
|
Academic Article
|
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
|
Academic Article
|
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.
|
Academic Article
|
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
|
Academic Article
|
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
|
Academic Article
|
Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?
|
Academic Article
|
Update on pharmacogenetics in cancer chemotherapy.
|
Academic Article
|
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
|
Academic Article
|
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
|
Academic Article
|
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
|
Academic Article
|
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations.
|
Academic Article
|
Laboratory and clinical studies of biochemical modulation by hydroxyurea.
|
Academic Article
|
Endostatin: are the 2 years up yet?
|
Academic Article
|
Conflict-of-interest policies.
|
Academic Article
|
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
|
Academic Article
|
Anticancer drug discovery and development throughout the world.
|
Academic Article
|
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
|
Academic Article
|
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
|
Academic Article
|
A phase I study of liposomal doxorubicin (Doxil) with topotecan.
|
Academic Article
|
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism.
|
Academic Article
|
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
|
Academic Article
|
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
Academic Article
|
Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia.
|
Academic Article
|
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
|
Academic Article
|
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.
|
Academic Article
|
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
Academic Article
|
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
|
Academic Article
|
Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
|
Academic Article
|
In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes.
|
Academic Article
|
Hairy cell leukaemia: the role of alpha interferon.
|
Academic Article
|
Pharmacogenomics: road to anticancer therapeutics nirvana?
|
Academic Article
|
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
|
Academic Article
|
Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.
|
Academic Article
|
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).
|
Academic Article
|
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
|
Academic Article
|
Paradoxical relationship between acetylator phenotype and amonafide toxicity.
|
Academic Article
|
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
|
Academic Article
|
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.
|
Academic Article
|
"Irinogenetics" and UGT1A: from genotypes to haplotypes.
|
Academic Article
|
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
|
Academic Article
|
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
|
Academic Article
|
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
|
Academic Article
|
Randomized discontinuation design: application to cytostatic antineoplastic agents.
|
Academic Article
|
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.
|
Academic Article
|
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
Academic Article
|
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
|
Academic Article
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
Academic Article
|
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
|
Academic Article
|
Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
|
Academic Article
|
UGT pharmacogenomics: implications for cancer risk and cancer therapeutics.
|
Academic Article
|
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
|
Academic Article
|
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
|
Academic Article
|
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
|
Academic Article
|
Phase II oncology trials: let's be positive.
|
Academic Article
|
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.
|
Academic Article
|
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
|
Academic Article
|
Personalized medicine: building the GPS to take us there.
|
Academic Article
|
Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver.
|
Academic Article
|
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
|
Academic Article
|
Global gene expression as a function of germline genetic variation.
|
Academic Article
|
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
|
Academic Article
|
Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor.
|
Academic Article
|
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.
|
Academic Article
|
Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".
|
Academic Article
|
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.
|
Academic Article
|
Finding the right dose.
|
Academic Article
|
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
|
Academic Article
|
Irinogenetics: what is the right star?
|
Academic Article
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
Academic Article
|
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
|
Academic Article
|
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing.
|
Academic Article
|
Effects of green tea compounds on irinotecan metabolism.
|
Academic Article
|
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
|
Academic Article
|
Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.
|
Academic Article
|
Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms.
|
Academic Article
|
Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.
|
Academic Article
|
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
|
Academic Article
|
The pharmacogenetics research network: from SNP discovery to clinical drug response.
|
Academic Article
|
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials.
|
Academic Article
|
Interpreting P values in pharmacogenetic studies: a call for process and perspective.
|
Academic Article
|
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
|
Academic Article
|
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
|
Academic Article
|
The value meal: how to save $1,700 per month or more on lapatinib.
|
Academic Article
|
Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration.
|
Academic Article
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
Academic Article
|
Modeling interpatient pharmacodynamic variability of etoposide.
|
Academic Article
|
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
|
Academic Article
|
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
|
Academic Article
|
Biomarkers in early cancer drug development: limited utility.
|
Academic Article
|
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
|
Academic Article
|
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
|
Academic Article
|
Genome-wide identification of genetic determinants for the cytotoxicity of perifosine.
|
Academic Article
|
Evaluation of Leu-M5 (CD11c) in hairy cell leukemia by the alkaline phosphatase anti-alkaline phosphatase technique.
|
Academic Article
|
Linkage disequilibrium across the UGT1A locus should not be ignored in association studies of cancer susceptibility.
|
Academic Article
|
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
|
Academic Article
|
EGFR pharmacogenomics: the story continues to mutate and evolve.
|
Academic Article
|
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
|
Academic Article
|
Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.
|
Academic Article
|
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.
|
Academic Article
|
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
|
Academic Article
|
A survey of the population genetic variation in the human kinome.
|
Academic Article
|
Conservative management of primary cervical lymphoma using combination chemotherapy: a case report.
|
Academic Article
|
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
|
Academic Article
|
Recent advances in the treatment of hairy-cell leukemia.
|
Academic Article
|
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
|
Academic Article
|
Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes.
|
Academic Article
|
Sequential treatment of hairy cell leukemia: a new role for interferon.
|
Academic Article
|
Etoposide pathway.
|
Academic Article
|
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.
|
Academic Article
|
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
|
Academic Article
|
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
|
Academic Article
|
Hairy cell leukemia. Current management.
|
Academic Article
|
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
|
Academic Article
|
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
|
Academic Article
|
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
|
Academic Article
|
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
|
Academic Article
|
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
|
Academic Article
|
A pharmacogenetic study of vorinostat glucuronidation.
|
Academic Article
|
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
|
Academic Article
|
Evaluating the activity of temsirolimus in neuroendocrine cancer.
|
Academic Article
|
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
|
Academic Article
|
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
|
Academic Article
|
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
|
Academic Article
|
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
|
Academic Article
|
Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.
|
Academic Article
|
A phase I study of continuous infusion cilengitide in patients with solid tumors.
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
Academic Article
|
Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?
|
Academic Article
|
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
|
Academic Article
|
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
|
Academic Article
|
Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
|
Academic Article
|
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.
|
Academic Article
|
The investigational drug steering committee.
|
Academic Article
|
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue.
|
Academic Article
|
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.
|
Academic Article
|
Flushing oral oncology drugs down the toilet.
|
Academic Article
|
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
|
Academic Article
|
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
|
Academic Article
|
Models of excellence: improving oncology drug development.
|
Academic Article
|
Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.
|
Academic Article
|
Why RECIST works and why it should stay--reply to counterpoint.
|
Academic Article
|
Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.
|
Academic Article
|
Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin.
|
Academic Article
|
Nonprofit biomedical companies.
|
Academic Article
|
Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia.
|
Academic Article
|
Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.
|
Academic Article
|
Limited sampling models for doxorubicin pharmacokinetics.
|
Academic Article
|
Optimising the design of phase II oncology trials: the importance of randomisation.
|
Academic Article
|
Phase I and pharmacological study of vinblastine by prolonged continuous infusion.
|
Academic Article
|
Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986.
|
Academic Article
|
Phase I study of escalating does of carboplatin.
|
Academic Article
|
Prognostic factors for survival in patients treated in phase I clinical trials.
|
Academic Article
|
Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions.
|
Academic Article
|
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
|
Academic Article
|
Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha 2 interferon for hairy cell leukemia.
|
Academic Article
|
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.
|
Academic Article
|
Bar the windows but open the door to randomization.
|
Academic Article
|
Resampling phase III data to assess phase II trial designs and endpoints.
|
Academic Article
|
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
|
Academic Article
|
Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.
|
Academic Article
|
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
|
Academic Article
|
A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.
|
Academic Article
|
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
|
Academic Article
|
Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia.
|
Academic Article
|
Durability of responses to interferon alfa-2b in advanced hairy cell leukemia.
|
Academic Article
|
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.
|
Academic Article
|
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.
|
Academic Article
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
Academic Article
|
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
|
Academic Article
|
Pharmacogenomics: will the promise be fulfilled?
|
Academic Article
|
Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions.
|
Academic Article
|
The role of interferon in the treatment of hairy cell leukemia.
|
Academic Article
|
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
|
Academic Article
|
The treatment of hairy cell leukemia: an update.
|
Academic Article
|
Randomized phase II trials: a long-term investment with promising returns.
|
Academic Article
|
Value-based insurance design: aligning incentives, benefits, and evidence in oncology.
|
Academic Article
|
Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
|
Academic Article
|
Pushing the envelope: informed consent in phase I trials.
|
Academic Article
|
Pharmacogenomics and patient care: one size does not fit all.
|
Academic Article
|
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
|
Academic Article
|
Sequential therapy with dacarbazine and carmustine: a phase I study.
|
Academic Article
|
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
|
Academic Article
|
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
|
Academic Article
|
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
|
Academic Article
|
Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b.
|
Academic Article
|
Cancer chemotherapy and skin changes.
|
Academic Article
|
Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.
|
Academic Article
|
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.
|
Academic Article
|
Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring.
|
Academic Article
|
A phase I study of intermittent infusion cladribine in patients with solid tumors.
|
Academic Article
|
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
|
Academic Article
|
Limited sampling model for vinblastine pharmacokinetics.
|
Academic Article
|
Changes in peripheral blood and bone marrow specimens during and after alpha 2b-interferon therapy for hairy cell leukemia.
|
Academic Article
|
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
|
Academic Article
|
A population model for the leukopenic effect of etoposide.
|
Academic Article
|
Bootstrap validation of pharmacodynamic models defined via stepwise linear regression.
|
Academic Article
|
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
|
Academic Article
|
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
|
Academic Article
|
Pharmacodynamics and long-term toxicity of etoposide.
|
Academic Article
|
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
|
Academic Article
|
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
|
Academic Article
|
Dose-escalation models for combination phase I trials in oncology.
|
Academic Article
|
Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
|
Academic Article
|
Low-dose interferon alfa-2b in the treatment of hairy cell leukemia.
|
Academic Article
|
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung.
|
Academic Article
|
Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity?
|
Academic Article
|
RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point.
|
Academic Article
|
Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine.
|
Academic Article
|
Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.
|
Academic Article
|
Limited sampling models for amonafide (NSC 308847) pharmacokinetics.
|
Academic Article
|
Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapy.
|
Academic Article
|
Interpatient and intrapatient variability in vinblastine pharmacokinetics.
|
Academic Article
|
Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986.
|
Academic Article
|
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
|
Academic Article
|
Perceptions of cancer patients and their physicians involved in phase I trials.
|
Academic Article
|
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials.
|
Academic Article
|
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
|
Academic Article
|
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
|
Academic Article
|
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
|
Academic Article
|
Simultaneous determination of 5-fluorouracil and uracil by high-performance liquid chromatography using four serial columns.
|
Academic Article
|
Drug combinations: dangerous liaisons or great expectations?
|
Academic Article
|
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
|
Academic Article
|
Body surface area as a determinant of pharmacokinetics and drug dosing.
|
Academic Article
|
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.
|
Academic Article
|
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
|
Academic Article
|
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
|
Academic Article
|
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
|
Academic Article
|
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
|
Academic Article
|
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
|
Academic Article
|
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
|
Academic Article
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
Academic Article
|
Modulation of vinblastine resistance with cyclosporine: a phase I study.
|
Academic Article
|
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
|
Academic Article
|
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.
|
Academic Article
|
Measuring response in a post-RECIST world: from black and white to shades of grey.
|
Academic Article
|
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
|
Academic Article
|
UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers.
|
Academic Article
|
Rapamycin: something old, something new, sometimes borrowed and now renewed.
|
Academic Article
|
Pharmacogenetic pathway analysis of irinotecan.
|
Academic Article
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
Academic Article
|
Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
|
Academic Article
|
Duration of response after interferon treatment of hairy cell leukemia.
|
Academic Article
|
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
|
Academic Article
|
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
|
Academic Article
|
Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
|
Academic Article
|
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
|
Academic Article
|
Value-based insurance design in oncology.
|
Academic Article
|
A limited sampling strategy for cyclophosphamide pharmacokinetics.
|
Academic Article
|
Phase-I trial of Thiotepa, granulocyte-macrophage colony-stimulating factor and prednisone or pentoxifylline in patients with refractory solid tumors.
|
Academic Article
|
Opportunities and challenges in the development of experimental drug combinations for cancer.
|
Academic Article
|
Oncology micro-cap stocks: caveat emptor!
|
Academic Article
|
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
|
Academic Article
|
Prognostic variables in hairy cell leukemia after splenectomy as initial therapy.
|
Academic Article
|
Skeletal complications in hairy cell leukemia: diagnosis and therapy.
|
Academic Article
|
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
|
Academic Article
|
Unsupported off-label chemotherapy in metastatic colon cancer.
|
Academic Article
|
Playing Russian roulette with tyrosine kinase inhibitors.
|
Academic Article
|
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
|
Academic Article
|
Cancer pharmacogenomics: strategies and challenges.
|
Academic Article
|
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.
|
Academic Article
|
A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection.
|
Academic Article
|
A genome-wide integrative study of microRNAs in human liver.
|
Academic Article
|
CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality.
|
Academic Article
|
Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer.
|
Academic Article
|
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.
|
Academic Article
|
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
|
Academic Article
|
Time to tumor growth: a model end point and new metric system for oncology clinical trials.
|
Academic Article
|
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
|
Academic Article
|
Genome-wide interrogation of longitudinal FEV1 in children with asthma.
|
Academic Article
|
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
|
Academic Article
|
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
|
Academic Article
|
Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design.
|
Academic Article
|
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
|
Academic Article
|
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
|
Academic Article
|
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
|
Academic Article
|
UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.
|
Academic Article
|
Targeted therapies: redefining the primary objective of phase I oncology trials.
|
Academic Article
|
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
|
Academic Article
|
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).
|
Academic Article
|
Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.
|
Academic Article
|
Tumour heterogeneity in the clinic.
|
Academic Article
|
Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.
|
Academic Article
|
Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene.
|
Academic Article
|
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
|
Academic Article
|
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
|
Academic Article
|
Are drug labels static or dynamic?
|
Academic Article
|
Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science.
|
Academic Article
|
Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.
|
Academic Article
|
Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression.
|
Academic Article
|
Unmet needs in preventing adverse drug-drug interactions.
|
Academic Article
|
Conventional dosing of anticancer agents: precisely wrong or just inaccurate?
|
Academic Article
|
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).
|
Academic Article
|
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
|
Academic Article
|
Vemurafenib oral bioavailability: an insoluble problem.
|
Academic Article
|
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance).
|
Academic Article
|
Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project".
|
Academic Article
|
The development of a financial toxicity patient-reported outcome in cancer: The COST measure.
|
Academic Article
|
Forecasting unanticipated consequences of "The Sunshine Act": mostly cloudy.
|
Academic Article
|
Establishment of CYP2D6 reference samples by multiple validated genotyping platforms.
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
|
Academic Article
|
Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver.
|
Academic Article
|
User beware: we need more science and less art when measuring financial toxicity in oncology.
|
Academic Article
|
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
|
Academic Article
|
The impact of industry on oncology research and practice.
|
Academic Article
|
Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.
|
Academic Article
|
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.
|
Academic Article
|
Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).
|
Academic Article
|
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
|
Academic Article
|
In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7.
|
Academic Article
|
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
|
Academic Article
|
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
|
Academic Article
|
Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs.
|
Academic Article
|
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.
|
Academic Article
|
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.
|
Academic Article
|
The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone.
|
Academic Article
|
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.
|
Academic Article
|
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
|
Academic Article
|
Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials.
|
Academic Article
|
A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer.
|
Academic Article
|
Disease-drug database for pharmacogenomic-based prescribing.
|
Academic Article
|
Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2B.
|
Academic Article
|
Low Dose Interferon Alfa-2B for the Induction of Remission of Hairy Cell Leukemia: A Multi-institutional Study of 49 Patients.
|
Academic Article
|
Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration.
|
Academic Article
|
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).
|
Academic Article
|
Drug-Drug Interactions With Oral Antineoplastic Agents.
|
Academic Article
|
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.
|
Academic Article
|
ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.
|
Academic Article
|
Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.
|
Academic Article
|
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program.
|
Academic Article
|
Obviating the Need for Serial Biopsies Through Random Assignment.
|
Academic Article
|
Food Effect Studies for Oncology Drug Products.
|
Academic Article
|
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
|
Academic Article
|
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.
|
Academic Article
|
A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC).
|
Academic Article
|
Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations.
|
Academic Article
|
A study of informed consent (IC), age, and cognitive performance (CP) among advanced cancer patients (acp) in phase I trials.
|
Academic Article
|
Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781.
|
Academic Article
|
Analysis of phase II studies for the year 2002: Design, conclusions and impact factors of oncology vs. non-oncology trials.
|
Academic Article
|
A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors.
|
Academic Article
|
Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
|
Academic Article
|
Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms.
|
Academic Article
|
A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies.
|
Academic Article
|
Development of a pharmacokinetically-guided gemcitabine (dFdC) dosing schedule to reduce potentially excessive plasma dFdC concentrations.
|
Academic Article
|
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.
|
Academic Article
|
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
|
Academic Article
|
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
|
Academic Article
|
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).
|
Academic Article
|
Metabolism of megestrol acetate in vitro and the role of oxidative metabolites.
|
Academic Article
|
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
|
Academic Article
|
Genetic variation determines VEGF-A plasma levels in cancer patients.
|
Academic Article
|
Essential Characteristics of Pharmacogenomics Study Publications.
|
Academic Article
|
A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).
|
Academic Article
|
Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system.
|
Academic Article
|
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
|
Academic Article
|
The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost.
|
Academic Article
|
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
|
Academic Article
|
Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.
|
Academic Article
|
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
|
Academic Article
|
Low-Dose Abiraterone With Food: Rebutting an Editorial.
|
Academic Article
|
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
|
Academic Article
|
Time Is Money: Optimizing the Scheduling of Nivolumab.
|
Academic Article
|
Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.
|
Academic Article
|
Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.
|
Academic Article
|
Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study.
|
Academic Article
|
Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing.
|
Academic Article
|
Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.
|
Academic Article
|
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
|
Academic Article
|
Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.
|
Academic Article
|
Enhancing the Visibility and Prestige of Clinical Pharmacology as a Medical Subspecialty.
|
Academic Article
|
Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.
|
Academic Article
|
Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement.
|
Academic Article
|
Pharmacogenomic considerations for medications in the perioperative setting.
|
Academic Article
|
The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care.
|
Academic Article
|
Assessment of Patient Knowledge and Perceptions of Pharmacogenomics Before and After Using a Mock Results Patient Web Portal.
|
Academic Article
|
Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation.
|
Academic Article
|
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
|
Academic Article
|
A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting".
|
Academic Article
|
Alternative dosing regimens for atezolizumab: right dose, wrong frequency.
|
Academic Article
|
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
|
Academic Article
|
A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes.
|
Academic Article
|
Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients.
|
Academic Article
|
Pharmacogenomic-Based Decision Support to Predict Adherence to Medications.
|
Academic Article
|
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value.
|
Academic Article
|
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
|
Academic Article
|
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Letter.
|
Academic Article
|
Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.
|
Academic Article
|
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
|
Academic Article
|
Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.
|
Academic Article
|
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
|
Academic Article
|
Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change.
|
Academic Article
|
Patient insights on features of an effective pharmacogenomics patient portal.
|
Academic Article
|
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
|
Academic Article
|
Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab.
|
Academic Article
|
Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial.
|
Academic Article
|
Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis.
|
Academic Article
|
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments.
|
Academic Article
|
Influence of N-acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib.
|
Academic Article
|
The Right Dose: From Phase I to Clinical Practice.
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|
Academic Article
|
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance).
|
Academic Article
|
Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform.
|
Academic Article
|
Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application.
|
Academic Article
|
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
|
Academic Article
|
Creation of a pharmacogenomics patient portal complementary to an existing institutional provider-facing clinical decision support system.
|
Academic Article
|
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
|
Academic Article
|
Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?
|
Academic Article
|
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
|
Academic Article
|
Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care.
|
Academic Article
|
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
|
Academic Article
|
Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics.
|
Academic Article
|
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
|
Academic Article
|
Subcutaneous Atezolizumab: A Jab Without a Benefit.
|
Academic Article
|
Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
|
Academic Article
|
Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial.
|
Academic Article
|
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings.
|
Academic Article
|
Lurbinectedin-induced thrombocytopenia: the role of body surface area.
|
Academic Article
|
Lorlatinib Exposed: A Far From Optimal Dose.
|
Academic Article
|
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
|
Academic Article
|
Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension.
|
Academic Article
|
Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan.
|
Academic Article
|
Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware.
|
Academic Article
|
An Expanded Role for IRBs in the Oversight of Research Biopsies.
|
Academic Article
|
In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
|
Academic Article
|
US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?
|
Concept
|
Atazanavir Sulfate
|
Concept
|
Werner Syndrome Helicase
|
Concept
|
Cancer Survivors
|
Concept
|
Peroxisome-Targeting Signal 1 Receptor
|
Concept
|
Solute Carrier Organic Anion Transporter Family Member 1B3
|
Concept
|
Drug-Related Side Effects and Adverse Reactions
|
Concept
|
Response Evaluation Criteria in Solid Tumors
|
Concept
|
Proton Magnetic Resonance Spectroscopy
|
Academic Article
|
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.
|
Academic Article
|
Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions.
|
Academic Article
|
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies.
|
Academic Article
|
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?
|
Academic Article
|
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
|
Academic Article
|
Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?
|
Academic Article
|
An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States.
|
Academic Article
|
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-ß2 levels in metastatic colorectal cancer patients (Alliance).
|
Academic Article
|
Special designations and the US Food and Drug Administration's "dual mandate".
|
Academic Article
|
Optimizing the doses of cancer drugs after usual dose finding.
|
Academic Article
|
Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy.
|
Academic Article
|
Sotorasib dosing and incremental cost ineffectiveness - implications and lessons for stakeholders.
|